IL142255A0 - Method of treating heparin-induced thrombocytopenia - Google Patents
Method of treating heparin-induced thrombocytopeniaInfo
- Publication number
- IL142255A0 IL142255A0 IL14225599A IL14225599A IL142255A0 IL 142255 A0 IL142255 A0 IL 142255A0 IL 14225599 A IL14225599 A IL 14225599A IL 14225599 A IL14225599 A IL 14225599A IL 142255 A0 IL142255 A0 IL 142255A0
- Authority
- IL
- Israel
- Prior art keywords
- induced thrombocytopenia
- heparin
- provides
- treating heparin
- treating
- Prior art date
Links
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 229940127090 anticoagulant agent Drugs 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10843298P | 1998-11-13 | 1998-11-13 | |
| PCT/US1999/026770 WO2000029014A1 (en) | 1998-11-13 | 1999-11-10 | Method of treating heparin-induced thrombocytopenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL142255A0 true IL142255A0 (en) | 2002-03-10 |
Family
ID=22322154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14225599A IL142255A0 (en) | 1998-11-13 | 1999-11-10 | Method of treating heparin-induced thrombocytopenia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6743426B2 (enExample) |
| EP (1) | EP1128842B1 (enExample) |
| JP (1) | JP2002529515A (enExample) |
| CN (1) | CN1326355A (enExample) |
| AT (1) | ATE320263T1 (enExample) |
| AU (1) | AU1477000A (enExample) |
| BR (1) | BR9915317A (enExample) |
| CA (1) | CA2351067A1 (enExample) |
| DE (1) | DE69930419T2 (enExample) |
| ES (1) | ES2259248T3 (enExample) |
| IL (1) | IL142255A0 (enExample) |
| WO (1) | WO2000029014A1 (enExample) |
| ZA (1) | ZA200102722B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468358B2 (en) * | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| US20090054374A1 (en) * | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
| CA2694189A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| US9271999B2 (en) | 2012-05-09 | 2016-03-01 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US5550036A (en) | 1986-04-09 | 1996-08-27 | Eli Lilly And Company | Method for co-amplification of human protein C genes in human cells |
| US4992373A (en) | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5270178A (en) * | 1990-02-23 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
| IL97312A (en) | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
| US5831141A (en) * | 1991-01-11 | 1998-11-03 | United States Of America As Represented By The Department Of Health And Human Services | Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter |
| WO1992011757A1 (en) | 1991-01-11 | 1992-07-23 | American Red Cross | Expression of active human protein c in mammary tissue of transgenic animals |
| AT402262B (de) | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
| JPH05271098A (ja) * | 1992-03-26 | 1993-10-19 | Teijin Ltd | 活性化プロテインｃを有効成分とする抗血小板剤 |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| WO1997020043A1 (en) | 1995-11-30 | 1997-06-05 | Zymogenetics, Inc. | Protein c production in transgenic animals |
| EA199900862A1 (ru) * | 1997-03-24 | 2000-04-24 | Эли Лилли Энд Компани | Способ лечения сосудистых нарушений |
| CZ298429B6 (cs) * | 1997-04-28 | 2007-10-03 | Eli Lilly And Company | Stabilní lyofilizovaný prostredek |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
1999
- 1999-11-10 WO PCT/US1999/026770 patent/WO2000029014A1/en not_active Ceased
- 1999-11-10 AU AU14770/00A patent/AU1477000A/en not_active Abandoned
- 1999-11-10 EP EP99972105A patent/EP1128842B1/en not_active Expired - Lifetime
- 1999-11-10 ES ES99972105T patent/ES2259248T3/es not_active Expired - Lifetime
- 1999-11-10 BR BR9915317-3A patent/BR9915317A/pt not_active Application Discontinuation
- 1999-11-10 CN CN99813255A patent/CN1326355A/zh active Pending
- 1999-11-10 DE DE69930419T patent/DE69930419T2/de not_active Expired - Lifetime
- 1999-11-10 AT AT99972105T patent/ATE320263T1/de not_active IP Right Cessation
- 1999-11-10 JP JP2000582060A patent/JP2002529515A/ja active Pending
- 1999-11-10 IL IL14225599A patent/IL142255A0/xx unknown
- 1999-11-10 CA CA002351067A patent/CA2351067A1/en not_active Abandoned
-
2001
- 2001-04-03 ZA ZA200102722A patent/ZA200102722B/en unknown
- 2001-05-11 US US09/853,859 patent/US6743426B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200102722B (en) | 2002-05-03 |
| BR9915317A (pt) | 2001-08-07 |
| WO2000029014A1 (en) | 2000-05-25 |
| EP1128842B1 (en) | 2006-03-15 |
| AU1477000A (en) | 2000-06-05 |
| DE69930419T2 (de) | 2006-09-07 |
| ES2259248T3 (es) | 2006-09-16 |
| US6743426B2 (en) | 2004-06-01 |
| CN1326355A (zh) | 2001-12-12 |
| CA2351067A1 (en) | 2000-05-25 |
| ATE320263T1 (de) | 2006-04-15 |
| EP1128842A1 (en) | 2001-09-05 |
| US20010018050A1 (en) | 2001-08-30 |
| JP2002529515A (ja) | 2002-09-10 |
| DE69930419D1 (de) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69626660D1 (en) | 2-alkylpyrrolidine | |
| GR3037074T3 (en) | Protein kinase c inhibitors | |
| PT817627E (pt) | Inibidores da proteina cinase c | |
| BG103671A (en) | Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes | |
| BR9610838A (pt) | Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização. | |
| AU7585598A (en) | Raf kinase inhibitors | |
| ES2170174T3 (es) | Proceso continuo para la preparacion de poliamidas. | |
| EP1537861A3 (en) | Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation | |
| GB2368796A (en) | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | |
| IL156584A0 (en) | Substituted triazole diamine derivatives as kinase inhibitors | |
| BG102259A (en) | Compostions with controlled paroxetine release | |
| CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
| IL142220A0 (en) | Method of treating viral hemorrhagic fever | |
| HK1039449A1 (zh) | 治疗多发性硬化的方法 | |
| MX9605072A (es) | Dispositivo dispensador para pretratamiento. | |
| IL142255A0 (en) | Method of treating heparin-induced thrombocytopenia | |
| HU9700024D0 (en) | Imidazopyridin-azolidinones | |
| ZA200102727B (en) | Method of treating sickle cell disease or thalassemia. | |
| IL142249A0 (en) | Method of treating thrombocytopenic purpura and hemolytic uremic syndrome | |
| CA2294243A1 (en) | Novel cyanoaziridines for treating cancer | |
| MX9603305A (es) | Proceso mejorado para la ruptura de emulsiones de aceite. | |
| UA42749C2 (uk) | N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування | |
| ES2122912A1 (es) | Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales. | |
| EP0646651A3 (en) | Method for improving the treatment of leather. | |
| AU3145400A (en) | Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |